Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study-Reference-Cited by-同舟云学术

Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study

Published:2006-01 Issue:1 Volume:100 Page:133-138
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Alberts David S.,Hannigan Edward V.,Liu Ping-Yu,Jiang Caroline,Wilczynski Sharon,Copeland Larry,Markman Maurie

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference29 articles.

1. Cancer statistics 2005;Jemal;CA Cancer J. Clin.,2005

2. Ovarian carcinoma metastatic to the diaphragm: frequently undiagnosed at laparotomy;Bagley;J. Obstet. Gynecol.,1973

3. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study;Ozols;JCO,2003

4. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy. A Southwest Oncology Group and Gynecologic Oncology Group Trial;Markman;JCO,2003

5. Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy;Bolis;Cancer,1996

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ubiquitination network in the type I IFN‐induced antiviral signaling pathway;European Journal of Immunology;2023-05-28

2. Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8+ T cell exhaustion and curtails anti-PD-1 efficacy;Cell Reports;2022-11

3. Study Design Solutions for Adjuvant and Maintenance Therapy in Cancer: Ovarian Cancer as an Example;SN Comprehensive Clinical Medicine;2022-08-13

4. Arachidonic acid, a clinically adverse mediator in the ovarian cancer microenvironment, impairs JAK‐STAT signaling in macrophages by perturbing lipid raft structures;Molecular Oncology;2022-05-04

5. Principles of Chemotherapy, Targeted Therapy, and Immunotherapy in Gynaecological Malignancies;Fundamentals in Gynaecologic Malignancy;2022